Ind-Swift Laboratories Limited
INDSWFTLAB.BO
Bombay Stock Exchange215.15
INR
-6.55
- -
Ind-Swift Laboratories Limited
INDSWFTLAB.BO
(Bombay Stock Exchange)
Recent
price
215.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ind-Swift Laboratories Limited is a research-driven pharmaceutical company engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs), intermediates, and formulations through group collaborations. Founded in 1995 and headquartered in Chandigarh, India, the company operates globally with manufacturing facilities approved by leading regulatory agencies including USFDA. Its main product portfolio includes APIs across therapeutic segments such as cardiovascular health, antihistamine, antidiabetic, antipsychotic, antimigraine, Parkinson’s disease, antineoplastic, ADHD, analgesics, alcohol abstinence, and bone resorption inhibitors. The company also holds global leadership positions in the macrolide antibiotic segment. Ind-Swift Laboratories provides contract research and manufacturing services (CRAMS) with a dedicated state-of-the-art research center focused on developing complex and generic APIs. The company supports its global customer base with advanced process technology development, regulatory filings, and end-to-end manufacturing solutions. Besides APIs, Ind-Swift has diversified into manufacturing finished dosage formulations through group collaborations to cater to regulated international markets. Recent major developments include the approval of its merger with Ind-Swift Limited by the National Company Law Tribunal in late 2025, representing a significant strategic consolidation. The company also continues to expand its R&D capabilities and product offerings with new regulatory compliant processes and technologies in various therapeutic categories. Despite recent revenue contraction reported for the fiscal year ending March 2025, Ind-Swift maintains a strong focus on innovation and regulatory excellence to support its global pharmaceutical supply chain. Ind-Swift Laboratories operates in the pharmaceutical manufacturing and contract research segments, serving regulated markets worldwide with a workforce exceeding 3,000 employees. Its products and services are supported by six integrated manufacturing sites across India and a dedicated research center equipped with advanced facilities for continuous product and technology development. The company is publicly listed on the Bombay Stock Exchange and National Stock Exchange of India.